Core Insights - HCM's stock opened up by 3.41% on August 5, reaching $17.87 per share with a total market capitalization of $3.117 billion [1] - For the fiscal year ending December 31, 2024, HCM reported total revenue of $630 million, a decrease of 24.8% year-over-year, and a net profit attributable to shareholders of $37.729 million, down 62.56% year-over-year [1] - HCM is scheduled to release its mid-year report for fiscal year 2025 on August 7, prior to the market opening [1] Company Overview - HCM is recognized as one of China's first innovative pharmaceutical research and development companies focused on the global market [2] - Over the past 20 years, the company has established a comprehensive and integrated R&D innovation platform with world-class discovery and development capabilities [2] - HCM is dedicated to bringing its self-discovered anti-tumor candidate drugs to global patients, with three drugs already launched in China and the first drug also available in the U.S. [2] - The company has built a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer healthcare products [2] - HCM is listed on the NASDAQ Global Select Market, the Hong Kong Stock Exchange, and the AIM market of the London Stock Exchange [2]
和黄医药(US ADR)上涨3.41%，报17.87美元/股，总市值31.17亿美元